热门资讯> 正文
Incyte宣布欧盟批准与Xencor合作的淋巴瘤疗法
2025-12-18 00:52
- Incyte (INCY) announced on Wednesday that the European Commission approved a drug regimen containing its Xencor (XNCR)-partnered antibody drug Minjuvi as a late-line option for certain adults with follicular lymphoma, a blood cancer.
- Accordingly, the treatment, also known as tafasitamab, will be available in the EU with other lymphoma drugs, lenalidomide and rituximab, for adults with relapsed or refractory FL who have undergone at least one line of systemic therapy.
- The approval marks the second indication for Minjuvi in the region after the EC granted conditional approval for the drug in combination with lenalidomide for certain adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
- Incyte (INCY) markets Minjuvi under an exclusive global license agreement with Xencor (XNCR), whose XmAb drug technology was used in the development of the product.
More on Incyte, Xencor
- Tracking Baker Brothers Portfolio - Q3 2025 Update
- Incyte Corporation (INCY) Presents at The 67th American Society of Hematology (ASH) Annual Meeting - Slideshow
- Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH - Slideshow
- FDA fast-tracks Incyte drug for rare blood cancer
- LLY joins $1T club but doesn't feature in SA's top 10 large-cap healthcare stocks
推荐文章
华盛早报 | “AI威胁”波及华尔街！财富管理公司全线暴跌；豆包官宣“参战”！春节AI红包战愈演愈烈
美股机会日报 | 科技巨头迎利好？特朗普政府拟结构性豁免芯片关税；台积电1月销售额创历史新高，盘前股价涨近3%
一图看懂 | 净利大增60.7%！中芯国际Q4营收24.9亿美元，同比增长12.8%
美股机会日报 | 市场风格趋变？美银称接下来是小盘股的天下；金价重回5000美元上方，贵金属板块盘前齐升
新股暗盘 | 乐欣户外飙升超70%，中签一手账面浮盈4345港元；爱芯元智微涨超0.2%
高盛预计英伟达Q4营收达673亿美元 给出250美元目标股价
财报大跌背后：微软正在进行一场昂贵但精准的“利润置换”
港股IPO持续火热！下周6股排队上市，“A+H”占比一半
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
